Antithrombotic therapy in patients with coronary artery disease and with type 2 diabetes mellitus

Wiener Medizinische Wochenschrift

Volumn 160, Issue 1-2, 2010, Pages 30-38

  Farhan, Serdar ^a   Höchtl, Thomas ^a   Kautzky Willer, Alexandra ^b   Wojta, Johann ^b   Huber, Kurt ^a  

^a WILHELMINEN HOSPITAL   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Acute coronary syndrome; Coronary artery disease; Diabetes mellitus

Indexed keywords

3A,4,4A,5,6,7,8,8A,9,9A DECAHYDRO N [4 [2 [5 (3 FLUOROPHENYL) 2 PYRIDYL]VINYL] 3 METHYL 1 OXO 3H BENZO[F]ISOBENZOFURAN 7 YL]CARBAMIC ACID ETHYL ESTER; ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APIXABAN; CLOPIDOGREL; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; OTAMIXABAN; PLACEBO; PRASUGREL; RIVAROXABAN; THIENOPYRIDINE DERIVATIVE; TICAGRELOR; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ADVERSE OUTCOME; AGRANULOCYTOSIS; ANTICOAGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; LOW DRUG DOSE; NEUTROPENIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; ST SEGMENT ELEVATION; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; COMBINED MODALITY THERAPY; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; FIBRINOLYTIC AGENTS; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 77949861991     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10354-010-0747-8     Document Type: Review

References (86)

1. J Stamler O Vaccaro JD Neaton D Wentworth 1993 Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial Diabetes Care 16 434 444 10.2337/diacare.16.2.434 1:STN:280:DyaK3s7mtFyrtQ%3D%3D 8432214
2. SM Haffner S Lehto T Ronnemaa K Pyorala M Laakso 1998 Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N Engl J Med 339 4 229 234 10.1056/NEJM199807233390404 1:STN:280:DyaK1czivVKgsg%3D%3D 9673301 (Pubitemid 28350165)
3. JA Cantrill A D'Emanuele TL Dornan S Garcia 1995 A survey of drug treatment and outcomes in diabetic patients with acute myocardial infarcts J Clin Pharm Ther 20 4 207 213 10.1111/j.1365-2710.1995.tb00650.x 1:CAS:528:DyaK2MXosVeiu78%3D 8557784
4. TM MacDonald R Butler RW Newton AD Morris 1998 Which drugs benefit diabetic patients for secondary prevention of myocardial infarction? DARTS/MEMO Collaboration Diabet Med 15 4 282 289 10.1002/(SICI)1096-9136(199804)15: 4<282::AID-DIA591>3.0.CO;2-C 1:STN:280:DyaK1c3ksVOqsw%3D%3D 9585392 (Pubitemid 28168507)
5. KE Kip DP Faxon KM Detre W Yeh SF Kelsey JW Currier 1996 Coronary angioplasty in diabetic patients. The national heart, lung, and blood institute percutaneous transluminal coronary angioplasty registry Circulation 94 8 1818 1825 1:STN:280:DyaK2s%2FislGitA%3D%3D 8873655
6. B Stein WS Weintraub SP Gebhart CL Cohen-Bernstein R Grosswald HA Liberman, et al. 1995 Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty Circulation 91 4 979 989 1:STN:280:DyaK2M7ltlyksw%3D%3D 7850985
7. GM Reaven 1998 Insulin resistance and human disease: a short history J Basic Clin Physiol Pharmacol 9 2-4 387 406 1:CAS:528:DyaK1MXitVyntL4%3D 10212844
8. M Pahor BM Psaty CD Furberg 1998 New evidence on the prevention of cardiovascular events in hypertensive patients with type 2 diabetes J Cardiovasc Pharmacol 32 Suppl 2 S18 S23 1:CAS:528:DyaK1cXlslGjtr8%3D 9736437
9. JA Colwell RW Nesto 2003 The platelet in diabetes: focus on prevention of ischemic events Diabetes Care 26 7 2181 2188 10.2337/diacare.26.7.2181 12832332
10. A Natarajan AG Zaman SM Marshall 2008 Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents Diab Vasc Dis Res 5 2 138 144 10.3132/dvdr.2008.023 18537103
11. G Davi I Catalano M Averna A Notarbartolo A Strano G Ciabattoni, et al. 1990 Thromboxane biosynthesis and platelet function in type II diabetes mellitus N Engl J Med 322 25 1769 1774 1:CAS:528:DyaK3MXisVGgt7Y%3D 2345567
12. JA Colwell 1997 Aspirin therapy in diabetes Diabetes Care 20 11 1767 1771 1:STN:280:DyaK1c%2FhsFSgtQ%3D%3D 9353620
13. M Gawaz I Ott AJ Reininger FJ Neumann 1994 Effects of magnesium on platelet aggregation and adhesion. Magnesium modulates surface expression of glycoproteins on platelets in vitro and ex vivo Thromb Haemost 72 6 912 918 1:CAS:528:DyaK2MXivVygsr8%3D 7740463
14. AI Vinik T Erbas TS Park R Nolan GL Pittenger 2001 Platelet dysfunction in type 2 diabetes Diabetes Care 24 8 1476 1485 10.2337/diacare.24.8.1476 1:CAS:528:DC%2BD3MXmtlGit7s%3D 11473089
15. J Auwerx R Bouillon D Collen J Geboers 1988 Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus Arteriosclerosis 8 1 68 72 1:STN:280:DyaL1c7jtlGhtw%3D%3D 2449156
16. J Calles-Escandon SA Mirza BE Sobel DJ Schneider 1998 Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects Diabetes 47 2 290 293 10.2337/diabetes.47.2.290 1:CAS:528:DyaK1cXntVOhtA%3D%3D 9519730
17. J Sagel JA Colwell L Crook M Laimins 1975 Increased platelet aggregation in early diabetes mellitus Ann Intern Med 82 6 733 738 1:STN:280: DyaE2M7otF2msg%3D%3D 1138583
18. M Shechter CN Merz MJ Paul-Labrador S Kaul 2000 Blood glucose and platelet-dependent thrombosis in patients with coronary artery disease J Am Coll Cardiol 35 2 300 307 10.1016/S0735-1097(99)00545-8 1:CAS:528: DC%2BD3cXhs1elsLw%3D 10676673 (Pubitemid 30125517)
19. ME Stegenga SN van der Crabben M Levi AF de Vos MW Tanck HP Sauerwein, et al. 2006 Hyperglycemia stimulates coagulation, whereas hyperinsulinemia impairs fibrinolysis in healthy humans Diabetes 55 6 1807 1812 10.2337/db05-1543 1:CAS:528:DC%2BD28XlsF2ru7k%3D 16731846 (Pubitemid 44324136)
20. A Collier A Rumley AG Rumley JR Paterson JP Leach GD Lowe, et al. 1992 Free radical activity and hemostatic factors in NIDDM patients with and without microalbuminuria Diabetes 41 8 909 913 10.2337/diabetes.41.8.909 1:STN:280:DyaK38zjtFyhtA%3D%3D 1628764
21. JB McGill DJ Schneider CL Arfken CL Lucore BE Sobel 1994 Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients Diabetes 43 1 104 109 10.2337/diabetes.43.1.104 1:STN:280:DyaK2c%2FosFKqsA%3D%3D 8262307
22. G Davi F Gennaro A Spatola I Catalano M Averna G Montalto, et al. 1992 Thrombin-antithrombin III complexes in type II diabetes mellitus J Diabetes Complications 6 1 7 11 10.1016/1056-8727(92)90042-J 1:STN:280: DyaK383itlCktw%3D%3D 1562762 (Pubitemid 23034744)
23. T Nagai 1994 Change of lipoprotein (a) and coagulative or fibrinolytic parameters in diabetic patients with nephropathy J Atheroscler Thromb 1 1 37 40 1:STN:280:DyaK2szms1SmtQ%3D%3D 9222867
24. Y Lopez MJ Paloma J Rifon B Cuesta JA Paramo 1999 Measurement of prethrombotic markers in the assessment of acquired hypercoagulable states Thromb Res 93 2 71 78 10.1016/S0049-3848(98)00165-0 1:CAS:528: DyaK1MXmt1KmsQ%3D%3D 9950260 (Pubitemid 29079462)
25. M Eliasson K Asplund PE Evrin B Lindahl D Lundblad 1994 Hyperinsulinemia predicts low tissue plasminogen activator activity in a healthy population: the Northern Sweden MONICA Study Metabolism 43 12 1579 1586 10.1016/0026-0495(94) 90020-5 1:CAS:528:DyaK2MXisFynur8%3D 7990715 (Pubitemid 24382712)
26. S Farhan C Winzer A Tura P Quehenberger C Bieglmaier OF Wagner, et al. 2006 Fibrinolytic dysfunction in insulin-resistant women with previous gestational diabetes Eur J Clin Invest 36 5 345 352 10.1111/j.1365-2362.2006. 01630.x 1:CAS:528:DC%2BD28XmtFOqsrw%3D 16634839
27. A Algra J van Gijn 1999 Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin J Neurol Neurosurg Psychiatry 66 2 255 10.1136/jnnp.66.2.255 1:STN:280:DyaK1M7mvVKkug%3D%3D 10071120
28. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ, 324(7329): 71-86, 2002
29. RM Cubbon CP Gale A Rajwani A Abbas C Morrell R Das, et al. 2008 Aspirin and mortality in patients with diabetes sustaining acute coronary syndrome Diabetes Care 31 2 363 365 10.2337/dc07-1745 17959865
30. M Sacco F Pellegrini MC Roncaglioni F Avanzini G Tognoni A Nicolucci 2003 Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial Diabetes Care 26 12 3264 3272 10.2337/diacare.26.12.3264 1:CAS:528:DC%2BD3sXpvF2ks7Y%3D 14633812 (Pubitemid 37466885)
31. J Belch A MacCuish I Campbell S Cobbe R Taylor R Prescott, et al. 2008 The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease BMJ 337 a1840 10.1136/bmj.a1840 18927173
32. H Ogawa M Nakayama T Morimoto S Uemura M Kanauchi N Doi, et al. 2008 Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial JAMA 300 18 2134 2141 10.1001/jama.2008.623 1:CAS:528:DC%2BD1cXhtlOrtLnM 18997198
33. F Balsano P Rizzon F Violi D Scrutinio C Cimminiello F Aguglia, et al. 1990 Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group Circulation 82 1 17 26 1:STN:280:DyaK3czgsFSqsw%3D%3D 2194694
34. F Van de Werf J Bax A Betriu C Blomstrom-Lundqvist F Crea V Falk, et al. 2008 Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-segment elevation acute myocardial infarction of the European society of cardiology Eur Heart J 29 23 2909 2945 10.1093/eurheartj/ehn416 1:CAS:528: DC%2BD1MXmtl2hsw%3D%3D 19004841
35. Kushner FG, Hand M, Smith SC Jr., King SB 3rd, Anderson JL, Antman EM, et al. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update) A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 54(23): 2205-2241, 2009
36. T Szuk M Gyongyosi N Homorodi E Kristof C Kiraly IF Edes, et al. 2007 Effect of timing of clopidogrel administration on 30-day clinical outcomes: 300-mg loading dose immediately after coronary stenting versus pretreatment 6 to 24 hours before stenting in a large unselected patient cohort Am Heart J 153 2 289 295 10.1016/j.ahj.2006.10.030 17239691 (Pubitemid 46096860)
37. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE steering committee. Lancet, 348(9038): 1329-1339, 1996
38. S Yusuf F Zhao SR Mehta S Chrolavicius G Tognoni KK Fox 2001 Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 7 494 502 10.1056/NEJMoa010746 1:CAS:528:DC%2BD3MXms1arsrY%3D 11519503 (Pubitemid 32758501)
39. SR Steinhubl PB Berger JT Mann 3rd ET Fry A DeLago C Wilmer, et al. 2002 Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial JAMA 288 19 2411 2420 10.1001/jama.288.19.2411 1:CAS:528:DC%2BD38XoslOksL0%3D 12435254 (Pubitemid 35340537)
40. DJ Angiolillo SB Shoemaker B Desai H Yuan RK Charlton E Bernardo, et al. 2007 Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the optimizing antiplatelet therapy in diabetes mellitus (OPTIMUS) study Circulation 115 6 708 716 10.1161/CIRCULATIONAHA.106.667741 1:CAS:528:DC%2BD2sXhtlGqtbg%3D 17261652 (Pubitemid 46294761)
41. SD Wiviott E Braunwald CH McCabe G Montalescot W Ruzyllo S Gottlieb, et al. 2007 Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 20 2001 2015 10.1056/NEJMoa0706482 1:CAS:528:DC%2BD2sXhtlWis7rN 17982182 (Pubitemid 350106708)
42. RE Wrishko CS Ernest 2nd DS Small YG Li GJ Weerakkody JR Riesmeyer, et al. 2009 Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38 J Clin Pharmacol 49 8 984 998 10.1177/0091270009337942 1:CAS:528:DC%2BD1MXhtVSqurzM 19546250
43. T Jernberg CD Payne KJ Winters C Darstein JT Brandt JA Jakubowski, et al. 2006 Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease Eur Heart J 27 10 1166 1173 10.1093/eurheartj/ehi877 1:CAS:528:DC%2BD28Xls1Crt7g%3D 16621870 (Pubitemid 43752387)
44. EM Antman SD Wiviott SA Murphy J Voitk Y Hasin P Widimsky, et al. 2008 Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis J Am Coll Cardiol 51 21 2028 2033 10.1016/j.jacc.2008.04.002 1:CAS:528:DC%2BD1cXmtlWht7w%3D 18498956
45. SA Murphy EM Antman SD Wiviott G Weerakkody G Morocutti K Huber, et al. 2008 Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial Eur Heart J 29 20 2473 2479 10.1093/eurheartj/ehn362 1:CAS:528: DC%2BD1cXhsVSjtbfL 18682445
46. SA Spinler C Rees 2009 Review of prasugrel for the secondary prevention of atherothrombosis J Manag Care Pharm 15 5 383 395 19496635
47. SD Wiviott E Braunwald DJ Angiolillo S Meisel AJ Dalby FW Verheugt, et al. 2008 Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38 Circulation 118 16 1626 1636 10.1161/CIRCULATIONAHA.108.791061 1:CAS:528:DC%2BD1cXht1SntLrI 18757948
48. G Montalescot SD Wiviott E Braunwald SA Murphy CM Gibson CH McCabe, et al. 2009 Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial Lancet 373 9665 723 731 10.1016/S0140-6736(09)60441-4 1:CAS:528:DC%2BD1MXisVOrsbc%3D 19249633
49. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med, 361(11): 1045-1057
50. M Roffi DP Chew D Mukherjee DL Bhatt JA White C Heeschen, et al. 2001 Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes Circulation 104 23 2767 2771 10.1161/hc4801.100029 1:CAS:528:DC%2BD38XivFarsQ%3D%3D 11733392
51. SP Marso AM Lincoff SG Ellis DL Bhatt JF Tanguay NS Kleiman, et al. 1999 Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy Circulation 100 25 2477 2484 1:STN:280:DC%2BD3c%2Fnt1GqtA%3D%3D 10604884
52. AM Lincoff RM Califf DJ Moliterno SG Ellis J Ducas JH Kramer, et al. 1999 Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of platelet IIb/IIIa inhibition in stenting investigators N Engl J Med 341 5 319 327 10.1056/NEJM199907293410503 1:CAS:528:DyaK1MXltVKgs7o%3D 10423466 (Pubitemid 29350302)
53. J Mehilli A Kastrati H Schuhlen A Dibra F Dotzer N von Beckerath, et al. 2004 Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel Circulation 110 24 3627 3635 10.1161/01.CIR.0000148956. 93631.4D 1:CAS:528:DC%2BD2cXhtVCisbvP 15531766 (Pubitemid 40003783)
54. G De Luca CM Gibson F Bellandi M Noc D Dudek U Zeymer, et al. 2009 Diabetes mellitus is associated with distal embolization, impaired myocardial perfusion, and higher mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty and glycoprotein IIb-IIIa inhibitors Atherosclerosis 207 1 181 185 10.1016/j.atherosclerosis.2009.03.042 1:CAS:528:DC%2BD1MXhtlyrtbfM 19426981
55. KA Fox EM Antman M Cohen F Bigonzi 2002 Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris/non-ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention Am J Cardiol 90 5 477 482 10.1016/S0002-9149(02)02517-1 1:CAS:528:DC%2BD38Xms1yntrY%3D 12208405 (Pubitemid 35246035)
56. EM Antman CH McCabe EP Gurfinkel AG Turpie PJ Bernink D Salein, et al. 1999 Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial Circulation 100 15 1593 1601 1:CAS:528:DyaK1MXmvFGnt7Y%3D 10517729
57. M Cohen C Demers EP Gurfinkel AG Turpie GJ Fromell S Goodman, et al. 1997 A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and safety of subcutaneous enoxaparin in non-Q-wave coronary events study group N Engl J Med 337 7 447 452 10.1056/NEJM199708143370702 1:CAS:528:DyaK2sXls1Ors7w%3D 9250846 (Pubitemid 27333045)
58. JJ Ferguson RM Califf EM Antman M Cohen CL Grines S Goodman, et al. 2004 Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial JAMA 292 1 45 54 10.1001/jama.292.1.45 1:CAS:528:DC%2BD2cXls1elsrg%3D 15238590 (Pubitemid 38923793)
59. JL Petersen KW Mahaffey V Hasselblad EM Antman M Cohen SG Goodman, et al. 2004 Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes: a systematic overview JAMA 292 1 89 96 10.1001/jama.292.1.89 1:CAS:528:DC%2BD2cXls1elt7s%3D 15238596 (Pubitemid 38923799)
60. JP Bassand CW Hamm D Ardissino E Boersma A Budaj F Fernandez-Aviles, et al. 2007 Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes Eur Heart J 28 13 1598 1660 10.1093/eurheartj/ehm161 1:CAS:528:DC%2BD2sXpslKmtLw%3D 17569677 (Pubitemid 47227122)
61. KW Mahaffey M Cohen J Garg E Antman NS Kleiman SG Goodman, et al. 2005 High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial JAMA 294 20 2594 2600 10.1001/jama.294.20.2594 1:CAS:528:DC%2BD2MXht1KitrnJ 16304073 (Pubitemid 41697241)
62. SH Baird IB Menown SJ McBride TG Trouton C Wilson 2002 Randomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction Eur Heart J 23 8 627 632 10.1053/euhj.2001.2940 1:CAS:528:DC%2BD38XktlWhur0%3D 11969277 (Pubitemid 35204247)
63. AM Ross P Molhoek C Lundergan M Knudtson Y Draoui L Regalado, et al. 2001 Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of heparin and aspirin reperfusion therapy (HART II) Circulation 104 6 648 652 10.1161/hc3101.093866 1:CAS:528:DC%2BD3MXmvFGntLY%3D 11489769
64. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet, 358(9282): 605-613, 2001
65. L Wallentin P Goldstein PW Armstrong CB Granger AA Adgey HR Arntz, et al. 2003 Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the assessment of the safety and efficacy of a new thrombolytic regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction Circulation 108 2 135 142 10.1161/01.CIR.0000081659.72985.A8 1:CAS:528:DC%2BD3sXotFaht7o%3D 12847070 (Pubitemid 36871293)
66. JW Eikelboom DJ Quinlan SR Mehta AG Turpie IB Menown S Yusuf 2005 Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials Circulation 112 25 3855 3867 10.1161/CIRCULATIONAHA.105.573550 1:CAS:528:DC%2BD2MXhtlSqurnL 16344381 (Pubitemid 43739483)
67. EM Antman DA Morrow CH McCabe F Jiang HD White KA Fox, et al. 2005 Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the enoxaparin and thrombolysis reperfusion for acute myocardial infarction treatment-thrombolysis in myocardial infarction study 25 (ExTRACT-TIMI 25) Am Heart J 149 2 217 226 10.1016/j.ahj.2004.08.038 1:CAS:528:DC%2BD2MXitVejs7w%3D 15846258 (Pubitemid 40348526)
68. EM Antman DA Morrow CH McCabe SA Murphy M Ruda Z Sadowski, et al. 2006 Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction N Engl J Med 354 14 1477 1488 10.1056/NEJMoa060898 1:CAS:528:DC%2BD28XjtFWgsrY%3D 16537665
69. DA Morrow EM Antman SA Murphy J Qin M Ruda S Guneri, et al. 2007 Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the enoxaparin and thrombolysis reperfusion for acute myocardial infarction treatment-thrombolysis in myocardial Infarction study 25 (ExTRACT-TIMI 25) trial Am Heart J 154 6 1078 1084 10.1016/j.ahj.2007.07.027 1:CAS:528:DC%2BD2sXhtlCrsb%2FO 18035078 (Pubitemid 350116034)
70. U Zeymer A Gitt R Zahn C Junger T Bauer T Heer, et al. 2009 Efficacy and safety of enoxaparin in combination with and without GP IIb/IIIa inhibitors in unselected patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention EuroIntervention 4 4 524 528 19284076
71. HS Gurm IJ Sarembock DJ Kereiakes JJ Young RA Harrington N Kleiman, et al. 2005 Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus: an analysis from the randomized evaluation in percutaneous coronary intervention linking angiomax to reduced clinical events (REPLACE)-2 trial J Am Coll Cardiol 45 12 1932 1938 10.1016/j.jacc.2005.02.074 1:CAS:528:DC%2BD2MXlt1WhsL4%3D 15963389 (Pubitemid 40814111)
72. F Feit SV Manoukian R Ebrahimi CV Pollack EM Ohman MJ Attubato, et al. 2008 Safety and efficacy of bivalirudin monotherapy in patients with diabetes mellitus and acute coronary syndromes: a report from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial J Am Coll Cardiol 51 17 1645 1652 10.1016/j.jacc.2007.11.081 1:CAS:528:DC%2BD1cXlsFyjtLs%3D 18436116
73. HD White DP Chew JW Hoekstra CD Miller CV Pollack Jr F Feit, et al. 2008 Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial J Am Coll Cardiol 51 18 1734 1741 10.1016/j.jacc.2007.12.052 1:CAS:528: DC%2BD1cXlsFOjtLY%3D 18452778
74. HD White EM Ohman AM Lincoff ME Bertrand A Colombo BT McLaurin, et al. 2008 Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial J Am Coll Cardiol 52 10 807 814 10.1016/j.jacc.2008.05.036 1:CAS:528:DC%2BD1cXhtVKju7jI 18755342
75. R Mehran AJ Lansky B Witzenbichler G Guagliumi JZ Peruga BR Brodie, et al. 2009 Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial Lancet 374 9696 1149 1159 10.1016/S0140-6736(09)61484-7 19717185
76. MJ Sculpher G Lozano-Ortega J Sambrook S Palmer O Ormanidhi A Bakhai, et al. 2009 Fondaparinux versus enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the fifth organization to assess strategies in acute ischemic syndromes investigators (OASIS-5) trial Am Heart J 157 5 845 852 10.1016/j.ahj.2009.02.017 1:CAS:528:DC%2BD1MXkslGns7g%3D 19376310
77. Peters R, SR M. Mortality benefit of fondaparinux versus enoxaparin in diabetic patients with non-ST elevation acute coronary syndrome (NSTE-ACS): a subanalysis of OASIS-5. J Thromb Haemost, 5(Supplement 2): P-M-683, 2007
78. S Yusuf SR Mehta S Chrolavicius R Afzal J Pogue CB Granger, et al. 2006 Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial JAMA 295 13 1519 1530 10.1001/jama.295.13.joc60038 1:CAS:528:DC%2BD28Xjt12isbs%3D 16537725
79. J Oldgren L Wallentin R Afzal JP Bassand A Budaj S Chrolavicius, et al. 2008 Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment Eur Heart J 29 3 315 323 10.1093/eurheartj/ehm578 18084015
80. RJ Peters C Joyner JP Bassand R Afzal S Chrolavicius SR Mehta, et al. 2008 The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial Eur Heart J 29 3 324 331 10.1093/eurheartj/ehm616 18245119
81. JL Mega E Braunwald S Mohanavelu P Burton R Poulter F Misselwitz, et al. 2009 Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial Lancet 374 9683 29 38 10.1016/S0140-6736(09)60738-8 1:CAS:528:DC%2BD1MXotFCgtLc%3D 19539361
82. JH Alexander RC Becker DL Bhatt F Cools F Crea M Dellborg, et al. 2009 Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the apixaban for prevention of acute ischemic and safety events (APPRAISE) trial Circulation 119 22 2877 2885 10.1161/CIRCULATIONAHA.108.832139 19470889
83. MS Sabatine EM Antman P Widimsky IO Ebrahim RG Kiss A Saaiman, et al. 2009 Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial Lancet 374 9692 787 795 10.1016/S0140-6736(09) 61454-9 1:CAS:528:DC%2BD1MXhtV2ksLnK 19717184
84. DA Morrow BM Scirica KA Fox G Berman J Strony E Veltri, et al. 2009 Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the thrombin-receptor antagonist in secondary prevention of atherothrombotic ischemic events (TRA 2 degrees P)-TIMI 50 trial Am Heart J 158 3 335 341 10.1016/j.ahj.2009.06.027 1:CAS:528:DC%2BD1MXhtVegs7bL 19699854 e3
85. RC Becker DJ Moliterno LK Jennings KS Pieper J Pei A Niederman, et al. 2009 Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study Lancet 373 9667 919 928 10.1016/S0140-6736(09) 60230-0 1:CAS:528:DC%2BD1MXjtFKqtrs%3D 19286091
86. The thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA*CER) trial: study design and rationale. Am Heart J, 158(3): 327-334 e4, 2009